Chromocell to Participate in the Virtual Investor Lunch Break Series
15 7월 2024 - 10:00PM
Chromocell Therapeutics Corporation (“Chromocell”, or the
“Company”), (NYSE American: CHRO), a pioneer in the development of
non-opioid pain treatment therapeutics, today announced that it
will present at the Virtual Investor Lunch Break: The Chromocell
Opportunity event on Thursday, July 18, 2024 at 12:00 PM ET.
As part of the event, Frank Knuettel II, Chief
Executive Officer and Chief Financial Officer of Chromocell, will
provide a corporate overview and business outlook. In addition to
the prepared remarks, interested parties will have the opportunity
to submit questions live during the event. Mr. Knuettel will answer
as many questions as possible in the time allowed.
A live video webcast of the event will be
available on the Events page under the Investors section of the
Company’s website (chromocell.com). A webcast replay will be
available two hours following the live event and will be accessible
for 90 days.
About Chromocell
Therapeutics
Chromocell Therapeutics Corporation is a
clinical-stage biotechnology company focused on developing and
commercializing novel, non-opioid, non-addictive therapeutics to
alleviate pain and other associated medical conditions. The
Company’s initial clinical focus is to selectively target the
sodium ion-channel known as NaV1.7 for the treatment of various
types of chronic neuropathic pain and acute and chronic eye pain.
The Company’s portfolio also includes pre-clinical work on other
sodium channel receptor subtypes, and the Company intends to
explore these and other compounds for the treatment of additional
pain indications. For company updates and to learn more about
Chromocell, visit www.chromocell.com or follow us on social
media.
Investor Contact:
LR Advisors LLC.Jason
Assad678-570-6791Jason@Chromocell.com
Chromocell Therapeutics (AMEX:CHRO)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Chromocell Therapeutics (AMEX:CHRO)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024